Bionomics Investor Presentation Deck
$3,000
$2,500
$2,000
$1,500
$1,000
$500
$0
PTSD Represents a Significant Unmet Need and Market Opportunity
No newly approved pharmacotherapy in almost two decades
BNC210 US PTSD Sales ($M)
388
Bionomics
2,604
2,360
1,711
ill
2027
2033
2036
BNC210 could achieve $2.6B in US
annual peak sales in PTSD*
2030
~7M
~9M
75% of adults
inadequately
treated ²
Opportunity
for BNC210
~21M
3.4%
prevalence
in adults
2. Only 20 to 30% of PTSD patients achieve clinical remission on SSRI therapies.
US Census Bureau. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html
*Based on 3rd party market analysis
8% of adults
at some
point in their
lives¹
Unmet medical need to large patient population
Advancement in care
Ability to potentially achieve large market share
1. Kilpatrick, D., Resnick, H., Milanak, M., Miller, M., Keyes, K. and Friedman, M., 2013. National Estimates of Exposure to Traumatic Events and PTSD Prevalence Using DSM-IV and DSM-5 Criteria.
Journal of Traumatic Stress, 26(5), pp.537-547; 2 Mayo LM, Asratain A., Lindé J et al. Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following
Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial. Biol Psychiatry. 2020 Mar 15; 87(6): 538-54
10View entire presentation